MDL® Isentris® platform selected by LEO Pharma

Discovery informatics architecture enhances R&D productivity by integrating informatics and workflow

SAN LEANDRO, CA – December TBD, 2005 – Elsevier MDL is pleased to announce that LEO Pharma, one of Denmark’s leading research-based pharma companies, has selected the complete MDL® Isentris® information management and integration platform for its R&D operations. As the first open-standards-based, n-tier discovery informatics platform specifically designed for life sciences researchers, Isentris is unique in effectively integrating the data and workflow applications scientists use every day and promoting a self-service research environment to enhance decision making and improve R&D productivity.

“LEO Pharma is a global company committed to developing innovative and efficacious products and associated services,” said Karsten Linneberg, head of section, R&D IT, department of spectroscopy, LEO Pharma. “As such, we are continually seeking to improve the day-to-day efficiency and productivity of our R&D teams. By playing a central role in integrating data and workflow applications and fostering knowledge-driven decisions, Isentris will accelerate and streamline LEO Pharma’s intensive R&D activities.”

“The complete MDL Isentris platform offers research organizations a clear path to better decisions, shorter cycle times and a higher return on investment,” said Lars Barfod, president & chief executive officer of Elsevier MDL. “We are delighted that LEO Pharma has elected to migrate from MDL® ISIS to the full suite of next-generation MDL Isentris products. This is further confirmation that Isentris is being accepted as the integrated informatics platform of choice for life sciences R&D organizations.”

The MDL® Isentris® Enterprise Edition platform includes the revolutionary MDL® Base user interface, MDL® Draw chemical drawing and rendering software, MDL® Core Interface middle tier with Integrating Data Source and the MDL® Direct chemical data cartridges for molecules and reactions. Full compatibility with MDL ISIS ensures easy transition to Isentris. For more information about MDL Isentris and associated data and workflow applications, visit

About Elsevier MDL
Elsevier MDL provides informatics, database and workflow solutions that accelerate successful life sciences R&D by improving the speed and quality of scientists’ decision making. Researchers around the world depend on Elsevier MDL for innovative and reliable discovery informatics software solutions and services augmented by 400 Elsevier chemistry and life sciences journals and related products. For more information, visit Elsevier is a world-leading publisher of scientific, technical and medical information products and services.

Elsevier is part of Reed Elsevier Group plc, a world-leading publisher and information provider. Reed Elsevier's ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange). For more information, visit

About Elsevier
Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Research Intelligence and ClinicalKey— and publishes over 2,500 journals, including The Lancet and Cell, and more than 35,000 book titles, including a number of iconic reference works. Elsevier is part of RELX Group, a world-leading provider of information and analytics for professional and business customers across industries.

Media Contact:
Dr. Phil McHale
Elsevier MDL
VP, Market and Corporate Communications
Phone: (510) 357-2222 ext. 3541


MDL and Isentris are registered trademarks of MDL Information Systems, Inc. (‘Elsevier MDL’) in the United States. All rights reserved. All other trademarks mentioned in this document are the property of their respective owners.